End-of-day quote
Korea S.E.
23:00:00 16/05/2024 BST
5-day change
1st Jan Change
7,430
KRW
-2.49%
+13.26%
-17.17%
Access Bio, Inc's Equity Buyback announced on March 24, 2022, has expired with 1,840,483 shares, representing 5.22% for KRW 29,899.64 million.
The company expired its plan on May 23, 2023.
Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc.
11/09/23
CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
26/05/23
CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
26/05/23
CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
26/05/23
CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
26/05/23
CI
Access Bio, Inc. agreed to acquire Belight Investment for approximately KRW 130 billion.
25/05/23
CI
Access Bio, Inc's Equity Buyback announced on March 24, 2022, has expired with 1,840,483 shares, representing 5.22% for KRW 29,899.64 million.
22/05/23
CI
Access Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/05/23
CI
Access Bio, Inc.'s Equity Buyback Plan Extended till May 23, 2023.
21/02/23
CI
AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency; BOS Up 2.6%
28/12/22
MT
AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency
28/12/22
MT
AirBoss of America Brief: Defense Logistics Agency has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at up to US$410 Million to Access Bio
28/12/22
MT
AirBoss of America Brief: AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency
28/12/22
MT
QuidelOrtho, Orasure Technologies, Others Share $803 Million Contract From US Defense Logistics Agency
23/11/22
MT
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
27/06/22
CI
Wellysis announced that it has received KRW 5 billion in funding from Access Bio, Inc.
29/05/22
CI
Access Bio, Inc. announces an Equity Buyback for KRW 30,000 million worth of its shares.
24/03/22
CI
Access Bio, Inc. authorizes a Buyback Plan.
23/03/22
CI
Access Bio, Inc. announced that it has received KRW 30 billion in funding from Meritz Securities Co., Ltd.
09/12/21
CI
Access Bio, Inc. announced that it expects to receive KRW 30 billion in funding from Meritz Securities Co., Ltd.
24/11/21
CI
Atomo Diagnostics Limited and Access Bio, Inc. Renegotiate Supply Agreements
05/10/21
CI
Vivera Pharmaceuticals Partners with Areum Bio LLC and Access Bio, Inc. to Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests
30/06/21
CI
Atomo Diagnostics Limited Receives FDA Clearance for Covid-19 Antibody Test
27/06/21
CI
Intrivo Diagnostics Secures National Distribution Agreement with McKesson Medical-Surgical for Access Bio CareStart™ COVID-19 Tests
17/12/20
CI
Access Bio, Inc.'s CareStart™ COVID-19 Antigen Test Kit Using NanoAct™ Launched in the U.S
08/12/20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Access Bio, Inc. is engaged in research, development and manufacturing of in vitro rapid diagnostic tests, biosensors and molecular diagnostic products. Its product list includes covid-19 detection kits, rapid diagnostic tests, analyzers and molecular diagnostics. Its covid-19 detection kits include CareStart COVID-19 Antigen Home Test, CareStart COVID-19 Antigen, CareStart COVID-19 MDx RT-PCR, CareStart COVID-19 lgM/lgG and CareStart EZ COVID-19 lgM/lgG. Its rapid diagnostic tests include CareStart EZ HIV, CareStart Flu A&B Plus+, CareStart G6PD RDT, CareStart Malaria RDT, CareStart Dengue RDT, care US HIV 1/2 and care US Syphilis. The analyzers include care SURE Analyzer 100, care SURE A1c Cartridge, care SURE ACR Cartridge, care SURE CRP Cartridge, care START S1 Analyzer and care START G6PD Biosensor. The molecular diagnostics include care GENE HPV Screening kit-H, care GENE Zika Virus RT-PCR kit, care GENE STD detection kit, care GENE Dengue Virus genotyping kit and others.
More about the company
1st Jan change
Capi.
-17.17% 191M -4.67% 12.33B -5.19% 8.14B +30.76% 5.62B -8.09% 4.24B -54.45% 3.06B +13.49% 2.76B -1.34% 2.41B +32.14% 2.23B -3.55% 1.87B
Diagnostic & Testing Substances
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1